Methoxetamine associated reversible cerebellar toxicity: three cases with analytical confirmation

Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists
Jennifer E ShieldsW Stephen Waring

Abstract

There have been recent concerns about increasing use and accessibility of methoxetamine, a ketamine derivative. Few data are available to describe the clinical features associated with methoxetamine exposure. We report three cases that presented to hospital with acute neurological toxicity associated with analytically confirmed methoxetamine exposure. A 19-year-old male presented with severe truncal ataxia, nystagmus, incoordination and reduced conscious level several hours after nasal insufflation of what was initially thought to be ketamine. Features of cerebellar toxicity persisted for 3-4 days before gradual recovery. Two more patients aged 17 and 18 years presented with severe cerebellar ataxia, imbalance and reduced conscious level 40 minutes after nasal insufflation of methoxetamine (MXE). Both had slurred speech, incoordination and cerebellar ataxia that resolved within 24 hours. Serum methoxetamine concentrations were 0.24 mg/L, 0.45 mg/L and 0.16 mg/L, respectively, and no other drugs were identified on an extended toxicological screen. Methoxetamine may cause rapid onset of neurological impairment, characterised by acute cerebellar toxicity. Spontaneous recovery was observed, but the duration of recovery may extend t...Continue Reading

References

Jun 21, 2011·The Journal of Urology·S K MakC Y Man
Aug 10, 2011·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·W Stephen Waring, Patricia McGettigan
Oct 11, 2011·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Jeanine WardEdward Boyer
Jan 18, 2012·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Simon Gibbons
Jan 25, 2012·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Christopher D RosenbaumKavita M Babu
Feb 4, 2012·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Mark B Mycyk
Oct 3, 2012·Therapeutische Umschau. Revue thérapeutique·S Hofer
Jan 1, 2011·Emerging Health Threats Journal·Sarbjeet S KalsiPaul I Dargan

❮ Previous
Next ❯

Citations

Nov 2, 2013·Journal of Psychoactive Drugs·Anette Kjellgren, Kristoffer Jonsson
Mar 4, 2014·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·P I DarganD T Yew
Feb 21, 2013·CNS Neuroscience & Therapeutics·Ornella CorazzaFabrizio Schifano
Mar 29, 2014·Drug Testing and Analysis·Hamilton Morris, Jason Wallach
Feb 18, 2014·Journal of Forensic Sciences·Albert A Elian, Jeffery Hackett
Jul 29, 2015·Human Psychopharmacology·Stefania ChiappiniFabrizio Schifano
Jul 26, 2014·International Journal of Occupational Medicine and Environmental Health·Marek WiergowskiZbigniew Jankowski
May 20, 2015·Forensic Science International : Synergy·R GiorgettiF Schifano
Aug 17, 2014·Toxicology Letters·Jolanta B Zawilska
Nov 22, 2014·Journal of Forensic Sciences·Piotr Adamowicz, Dariusz Zuba
Apr 11, 2015·Thérapie·François ChavantDanièle Debruyne
Jun 7, 2014·Journal of Analytical Toxicology·Laurent ImbertJean-Michel Gaulier
Jun 8, 2017·Journal of Psychoactive Drugs·Stephen ThorntonRoy Gerona
Sep 10, 2015·British Journal of Hospital Medicine·Kathleen S BonniciDavid M Wood
Feb 13, 2016·Behavioural Pharmacology·Cristiano ChiamuleraLiana Fattore
Jul 19, 2017·British Journal of Pharmacology·M T ZandaL Fattore
Apr 7, 2020·Archives of Toxicology·Dino Luethi, Matthias E Liechti
Nov 19, 2019·International Journal of Legal Medicine·Sabrina LehmannKatja Mercer-Chalmers-Bender
Jan 9, 2021·Therapeutic Advances in Psychopharmacology·Abu ShafiDerek K Tracy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.